Request Trial
jackie-7
26 November 2020Muireann Bolger

Five minutes with… Jacqueline Mulryne

Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect ’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
13 July 2026   The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.
Americas
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
Exelixis opens two-front patent dispute over Cabometyx copies
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies
UPC upholds injunction in Invisalign maker’s software dispute with rival
BioNTech and Pfizer secure big European win over mRNA patent
Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin
Influential Women in IP 2026: Who made the list?
WilmerHale trade secrets expert moves to new firm